Evidence map›Paper›PMID 26078000›Full record

ArticlePharmaceutical research2015

Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice.

Yoshinori Kato, Wenlian Zhu, Marina V Backer, Christopher C Neoh, Sudath Hapuarachchige, Susanta K Sarkar, Joseph M Backer, Dmitri Artemov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yoshinori Kato *Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Wenlian Zhu *Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Marina V BackerSibTech, Inc., Brookfield, CT 06804, USA.
Christopher C NeohDivision of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sudath HapuarachchigeDivision of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Susanta K SarkarCadenzaMed LLC, Wayne, PA 19087, USA.
Joseph M BackerSibTech, Inc., Brookfield, CT 06804, USA.
Dmitri ArtemovDivision of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

Image-guided combination therapy: noninvasive assessment of delivery and responseR01CA154738 · NCI · JOHNS HOPKINS UNIVERSITY · PI ARTEMOV, DMITRI, BACKER, JOSEPH M · 2011 to 2015
$2.9M
NCI NIH HHS CA154738NCI NIH HHS R01 CA154738
6 · The paper itself

Abstract

purposeMagnetic resonance imaging (MRI) is widely used for diagnostic imaging in preclinical studies and in clinical settings. Considering the intrinsic low sensitivity and poor specificity of standard MRI contrast agents, the enhanced delivery of MRI tracers into tumors is an important challenge to be addressed. This study was intended to investigate whether delivery of superparamagnetic iron oxide nanoparticles (SPIONs) can be enhanced by liposomal SPION formulations for either "passive" delivery into tumor via the enhanced permeability and retention (EPR) effect or "active" targeted delivery to tumor endothelium via the receptors for vascular endothelial growth factor (VEGFRs).

methodsIn vivo MRI of orthotopic MDA-MB-231 tumors was performed on a preclinical 9.4 T MRI scanner following intravenous administration of either free/non-targeted or targeted liposomal SPIONs.

resultsIn vivo MRI study revealed that only the non-targeted liposomal formulation provided a statistically significant accumulation of SPIONs in the tumor at four hours post-injection. The EPR effect contributes to improved accumulation of liposomal SPIONs in tumors compared to the presumably more transient retention during the targeting of the tumor vasculature via VEGFRs.

conclusionsA non-targeted liposomal formulation of SPIONs could be the optimal option for MRI detection of breast tumors and for the development of therapeutic liposomes for MRI-guided therapy.

Indexed as

AnimalsAntibiotics, AntineoplasticCell Line, TumorContrast MediaDoxorubicinFemaleFerrosoferric OxideHumansImmunohistochemistryLiposomesMagnetic Resonance ImagingMagnetite NanoparticlesMammary Neoplasms, ExperimentalMice, Inbred BALB CMice, NudeMolecular ImagingAntibiotics, AntineoplasticContrast MediaDoxorubicinFerrosoferric Oxideliposomal doxorubicinLiposomesMagnetite NanoparticlesPolyethylene GlycolsReceptors, Vascular Endothelial Growth Factorliposomesmagnetic resonance imaging (MRI)passive targetingsingle-chain vascular endothelial growth factor (scVEGF)superparamagnetic iron oxide nanoparticles (SPIONs)

Identifiers

PMID26078000
PMCPMC4600027

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.